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Abstract
Background:  PNRC transcriptionally regulates a wide range of RNA polymerase (pol) II-
transcribed genes by functioning as a nuclear receptor coactivator. To search for additional PNRC-
interacting proteins other than nuclear receptors, a PNRC fragment was used as bait in a yeast two-
hybrid screening of a human mammary gland cDNA expression library.
Results: RNA pol III/RPC39 fragments were repeatedly identified as PNRC-interacting partners in
two independent screenings. The interaction between these RPC39 fragments and PNRC was
further confirmed in the independent yeast two-hybrid assays. The association of endogenous
PNRC and RPC39 in MCF7 cells was demonstrated by co-immunoprecipitation. Furthermore,
ChIP analysis detected co-recruitment of PNRC and RPC39 to tRNA and U6 RNA promoters. The
biological consequence of the interaction between PNRC and RPC39 was further studied.
Overexpression of PNRC, either by transient or stable transfection, increased RNA pol III-
dependent transcription in MCF7 cells, while a decrease in transcription in MCF7 cells treated with
PNRC/siRNA was observed.
Conclusion: Here, we demonstrate that human PNRC stimulates RNA pol III transcription
through its interaction with the subunit RPC39 of RNA pol III.
PNRC is a unique coactivator that has profound effects on many aspects of cellular function by 
directly influencing both RNA pol II- and RNA pol III-dependent transcription.
Background
Nuclear receptors are ligand-dependent transcription fac-
tors that regulate the expression of various genes by bind-
ing to the specific hormone-responsive elements located
in the target gene promoters, thus playing essential roles
in development, differentiation, cell proliferation, and
metabolism. For the past few years, a great deal of progress
has been made in understanding the mechanisms by
which the nuclear receptors regulate gene transcription.
The function of nuclear receptors can be regulated by a
number of factors including ligand binding, DNA bind-
ing, interaction with other members in the family, interac-
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tion with basal transcription factors, and interaction with
coactivators and corepressors. Most of these coactivators
of nuclear receptors have molecular weights of ~160 kDa
and interact with the liganded nuclear receptors using a
short hydrophobic motif called NR-box or LXXLL-motif
[1].
Our studies to elucidate the mechanisms that regulate the
expression of the human aromatase gene in breast cancer
have identified and characterized a new family of coacti-
vator proteins, PNRC (proline-rich nuclear receptor coreg-
ulatory protein) [2] and PNRC2 [3]. PNRC and PNRC2
were identified as bovine SF-1 (steroidogenic factor 1)-
interacting proteins in a yeast two-hybrid screening of a
human mammary gland cDNA expression library. PNRC
and PNRC2 were found to interact with the ligand-bind-
ing domains of all the nuclear receptors tested, including
ER, PR, GR, TR, RAR, and RXR, in a ligand-dependent
manner. They were also found to interact in a ligand-inde-
pendent manner with the orphan receptors SF1 and estro-
gen receptor-related receptor alpha 1 (ERRα1). These
coactivators are unique in that they are significantly
smaller than most of the coregulatory proteins previously
identified and are proline-rich. Unlike most of the coacti-
vators that interact with nuclear receptors through its
LXXLL motif, these new coactivators interact with nuclear
receptors through a proline-rich Src homology domain-3
(SH3)-binding motif, S-D (E)-P-P-S-P-S [2,3].
In addition to functioning as a coactivator to activate the
transcription mediated by multiple nuclear receptors,
PNRC was recently found to down regulate the activation
of Ras and MAP kinase through interaction with Grb2, an
important adapter protein involved in growth factor/Ras
signaling pathway [4]. PNRC interacts with two SH3
domains of Grb2 through two SH3-binding motifs at its
N- and C-terminus. It is clear that Ras plays a central role
in mitogenic signaling. Consequently, inhibition of Ras
activation may therefore block the growth of malignant
cells that are dependent on activated Ras protein. Our pre-
vious data revealed that overexpression of PNRC in HeLa
cells suppressed Ras and MAP kinase activation and cell
growth [4].
In an attempt to gain insight into the mechanism of trans-
activation and signal transduction activities of PNRC, we
were interested in identifying cellular proteins other than
the nuclear receptors that specially interact with PNRC C-
terminus, which contains an SH3-binding motif. In this
study we employed the Gal4-based yeast two-hybrid sys-
tem to screen a human mammary gland cDNA expression
library with PNRC270–327 as bait for the proteins that asso-
ciate with C-terminal peptide of PNRC. The RNA
polymerase III subunit, RPC39, was isolated repeatedly
from two independent screenings. Here, we demonstrate
specific interaction of RPC39 with PNRC in vitro and in
vivo. Furthermore, our data from functional analysis pro-
vide evidence that the interaction between PNRC and
RPC39 plays a role in the activation of transcription by
RNA polymerase III. Thus, PNRC is a unique coactivator
regulating not only the transcription of wide range RNA
pol II-transcribed genes by functioning as nuclear receptor
coactivator, but also the transcription of genes transcribed
by RNA pol III through its direct interaction with a unique
subunit of human RNA pol III, RPC39.
Results
Identification of RPC39 as PNRC-interacting protein in the 
yeast two-hybrid screening
To identify additional proteins in breast tissue that inter-
act with PNRC, we have screened mammary gland cDNA
expression library twice with PNRC270–327 as bait using a
Gal4-based yeast two-hybrid approach. The human
PNRC270–327 yeast expression plasmid, pGBT9-PNRC270–
327, was used to transform yeast strain CG1945. The
CG1945 transformants bearing the pGBT9-PNRC270–327
plasmid were transformed again with a human mammary
gland cDNA library (Clontech) DNA. Approximately 3.0
~ 4.0 × 106 yeast transformants were screened in the
absence of nuclear receptor ligands to identify additional
PNRC-interacting proteins other than the nuclear recep-
tors, known to interact with PNRC. A total of 22 His+/β-
Gal+ clones were isolated from these two screening. To our
surprise, most of clones turned out to be PNRC itself, indi-
cating that PNRC can form a dimer. Among the other
PNRC-interacting clones, an RNA polymerase III subunit,
RPC39, was found. RPC39212–316 and RPC39241–316 were
isolated separately as PNRC270–327-interaction proteins in
each screen. Human RNA polymerase III transcribes genes
that produce small untranslated RNAs, including 5S
RNAs, tRNAs, U6 RNA, 7SK RNAs, and viral associated
RNAs such as adenovirus virus-associated (VA) RNAs.
Human RNA pol III is composed of at least 16 subunits
and three of these, hRPC32, hRPC39, and hRPC62, are
specific for RNA pol III and can form a subcomplex that
directs RNA Pol III binding to the TFIIIB-DNA complex
via the interaction between TFIIIB and hRPC39 [5]. To test
whether RPC39 truly interacts with PNRC and whether
this interaction is specific for PNRC, independent yeast
two-hybrid assays were performed to examine the interac-
tion between RPC39212–316  and PNRC270–327  or other
nuclear receptors and coactivators including PNRC2, SF1,
ER/HBD, mERR3/HBD, and an irrelevant protein such as
human lamin C protein (hLC). The expression of interact-
ing hybrid proteins in yeast transformants were analyzed
as LacZ expression. As shown in Fig. 1A, RPC39212–316 spe-
cifically interacts with PNRC270–327, but not with PNRC2,
SF1, ER/HBD, mERR3/HBD nor an irrelevant protein,
hLC, demonstrating that the interaction between
RPC39212–316 and PNRC270–327 is specific.Journal of Molecular Signaling 2007, 2:5 http://www.jmolecularsignaling.com/content/2/1/5
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PNRC interacts with the C-terminus, amino acids 212–316, 
of the human RNA pol III subunit RPC39
The two RPC39 clones originally isolated from the yeast
two-hybrid screening encoded two C-terminal peptides,
aa 212–316 and aa 241–316, respectively. These two
clones displayed similar abilities to interact with
PNRC270–327 in yeast two-hybrid assays as shown in Fig.
1B, suggesting that RPC39 interacts with PNRC through
its C-terminus. To test this hypothesis and to delineate
more precisely the protein domains involved in the inter-
action between RPC39 and PNRC, the yeast expression
plasmids for ADGal4-RPC39 wild type or ADGal4-RPC1–212
were constructed and tested in yeast two-hybrid assays for
their interaction with DBD-PNRC270–327. As shown in Fig.
1B, the C-terminal of RPC39, aa 212–316 region, was
found to interact as efficiently with PNRC270–327 as the
wild type protein. In contrast, the N-terminal region of
RPC39 (residues 1–212) did not detectably interact with
PNRC. Therefore, RPC39 interacts with PNRC through its
C-terminus.
PNRC associates with RPC39 in mammalian cells
To confirm by an independent method that PNRC inter-
acts with RPC39, we used coimmunoprecipitation assays
to determine whether PNRC associates with RPC39 in
mammalian cells. Due to a lack of commercial availability
of PNRC antibody and the high background of PNRC
antiserum generated in our laboratory, the MCF-7/EGFP-
PNRC cells that stably express EGFP-PNRC fusion protein
were used for this experiment. MCF-7/EGFP-PNRC cells
or MCF-7/EGFP cells (as a control) were transiently trans-
fected with the RPC39 expression plasmid, pSG5-RPC39.
To determine whether PNRC associates with RPC39 in
transfected MCF-7 cells, the EGFP-PNRC fusion protein
was immunoprecipitated from MCF-7/EGFP-PNRC cell
lysates with anti-GFP antibody and then the immunopre-
cipitates were analyzed with RPC39 antibody by Western
blot. As shown in Fig. 2A, a protein with a molecular
weight of 39 kDa was detected with the RPC39 antibody
in the anti-GFP immunoprecipitates (Fig. 2A, lane 2) as
well as in the crude protein extracts (lane 1) from MCF-7/
EGFP-PNRC cell lysates by Western blotting. These results
indicate that RPC39 protein coimmunoprecipitates with
EGFP-PNRC fusion protein. There was no RPC39 band
detected in the anti-GFP immunoprecipitates from MCF-
7/EGFP control cell lysate (Fig. 2A, lane 4) although
RPC39 was also expressed in the pSG5-RPC39 transfected
MCF-7/EGFP cells as shown in Fig. 2A, lane 3 (Fig. 2A,
lane 3), further demonstrating that RPC39 was associated
with PNRC portion of EGFP-PNRC fusion protein, not
EGFP portion of this fusion protein. To confirm the asso-
ciation of RPC39 and PNRC in vivo, we also immunopre-
cipitated RPC39 from the pSG5-RPC39 transfected MCF-
7/EGFP-PNRC cell lysate with anti-RPC39 antibody and
examined the presence of EGFP-PNRC protein in the
PNRC interacts with a subunit of RNA pol III Figure 1
PNRC interacts with a subunit of RNA pol III. A, 
ADGal4-RPC39212–316 expression plasmid was isolated from a 
human mammary gland expression library screening using 
DBDGal4-PNRC270–327 as bait. To confirm the interaction and 
the specificity of the interaction between PNRC and RPC39, 
yeast strain Y187 was cotransformed with the expression 
plasmids for the expression of the fusion proteins as indi-
cated, and transformants containing these plasmids were 
selected by growth on SD/-Leu/-Trp agar plates. The expres-
sion of interacting hybrid proteins in Y187 transformants was 
analyzed for LacZ expression. DBDGal4 (DBD) and DBDGal4-
human lamin C (hLC) expression plasmids were included as 
background and negative control, respectively. β-Galactosi-
dase activities in liquid cultures are expressed in Miller units 
as mean ± s.d. of three independent assays. B, PNRC inter-
acts with the C-terminus, amino acids 212–316, of the human 
Pol III subunit RPC39. The yeast expression plasmids, 
pACT2-RPC39 and pACT2-RPC391–212, for the expression 
of ADGal4-RPC39 wild type (WT) or ADGal4-RPC1–212 (1–
212) fusion proteins were constructed as described in 'Meth-
ods'. The expression plasmids for ADGal4-RPC39212–316 (212–
316) and ADGal4-RPC39241–316(241–316) were isolated from 
library screening through their interaction with PNRC270–327. 
Y187 cells were cotransformed with the expression plasmids 
coding for the fusion proteins as indicated. The selection of 
Y187 transformants and the β-Gal assays on transformants 
were performed as described in A.
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RPC39-immunoprecipitates. Results in Fig. 2B illustrated
that a protein with an apparent molecular weight of 60
kDa, which is close to the expected size of the EGFP-PNRC
fusion protein (28+35 kDa), was detected in the anti-
RPC39 immunoprecipitates (Fig. 2B, lane 2) as well as in
the crude protein extract derived from the transfected
MCF-7/EGFP-PNRC cells (Fig. 2B, lane 1), indicating that
PNRC was coimmunoprecipitated with RPC39 by anti-
RPC39 antibody. Therefore, the results from these experi-
ments demonstrate that PNRC associates with RPC39 in
vivo.
PNRC stimulates RNA pol III-dependent transcription
Since hRPC39 is a specific and important subunit of
human RNA pol III, it is tempting to speculate that the
interaction of PNRC and RPC39 may play a role in the
transcriptional regulation of genes transcribed by RNA pol
III/RPC39. To test this hypothesis, we sought to determine
the influence of PNRC overexpression on the transcrip-
tion of RNA pol III transcribed target genes. We first tran-
siently transfected MCF-7 cells with a reporter tRNA gene
plasmid to measure RNA pol III transcription in the pres-
ence of increasing amounts of PNRC expression plasmid,
pSG5-PNRC. tRNAarg transcripts were detected from the
transfected cells by RNase protection assay using a 32P-
labeled antisense riboprobe. As shown in Fig. 3, a dose-
dependent increase in tRNA gene transcription was
observed upon the introduction of increasing amounts of
PNRC expression plasmid (Fig. 3A). To confirm this
result, we then constructed stable cell lines expressing
increased PNRC protein, named MCF-7/PNRC cells. As
shown in Fig. 3B, the level of PNRC protein in MCF-7/
PNRC cells was much higher than that in the MCF-7 cells
transfected with vector alone (MCF-7/Vector). These sta-
ble cell lines were transiently transfected with the tRNA
gene reporter. Results in Fig. 3C illustrated that tRNA gene
transcription in the PNRC stable expression MCF-7 cells
was much higher than that in the control vector trans-
fected stable MCF-7 cells, supporting that overexpression
of PNRC, either by transient transfection or stable trans-
fection, stimulates the transcription directed by RNA pol
III.
Down regulation of RNA pol III-dependent transcription 
by specific depletion of endogenous PNRC using RNA 
interference
To further determine whether PNRC is a true activator of
RNA pol III, the influence of down regulation of PNRC on
transcription directed by RNA pol III in MCF-7 cells was
examined. MCF-7 cells were transfected with either siRNA
specific for PNRC (PNRC/siRNA) or nonspecific mis-
match RNA (mm). As shown in Fig. 4A, PNRC mRNA was
decreased dramatically by PNRC siRNA (lane 2) but not
by the introduction of nonspecific mismatched RNA (lane
1). As shown in Fig. 4B, EGFP-PNRC fusion protein was
decreased significantly upon the treatment of PNRC
siRNA (Fig. 4B, lane 2). The down regulation of PNRC by
PNRC/siRNA is specific as the level of GAPDH mRNA
(Fig. 4A, lower panel) and the level of actin protein (Fig.
4B, lower panel) in the cells did not change upon the
treatment of PNRC/siRNA. By knocking down the expres-
sion of PNRC in MCF-7 cells, PNRC/siRNA treatment also
remarkably reduced RNA pol III-transcribed tRNA gene
transcription by 5 fold (Fig. 4C). Together, these results
support that PNRC stimulates RNA polymerase III-
dependent transcription.
PNRC and RPC39 are co-recruited onto RNA polymerase 
III-dependent genes
The above experiments have demonstrated an interaction
between PNRC and RPC39 and the biological relevance of
this interaction in regulating transcription of genes tran-
PNRC associates with RPC39 in mammalian cells Figure 2
PNRC associates with RPC39 in mammalian cells. 
MCF-7/EGFP or MCF7/EGFP-PNRC stable expression cells 
were transiently transfected with the RPC39 expression plas-
mid, pSG5-RPC39, 24 h post-transfection, cells were har-
vasted and lysed, and 15 mg of total proteins were 
immunoprecipitated with antibodies against GFP (Clontech) 
or RPC39 (Santa Cruz Biotechnology). Specifically bound 
proteins to Protein A agarose beads were separated on a 
10% SDS-PAGE and analysed by immunoblotting with either 
anti-RPC39 (A, blot: anti-RPC39) or anti-GFP (B, blot: anti-
GFP) antibody, as previously described [2]. An aliquot of cell 
lysate equal to 100 µg of protein was included in each SDS-
PAGE gel for Western blot to examine whether the crude 
protein extracts used for co-immunoprecipitation contains 
EGFP-PNRC and RPC39 proteins. The protein bands with 
molecular weights corresponding to those of RPC39 or 
EGFP-PNRC were indicated by arrows.
A
Blot: anti-RPC39
IP         - GFP           - GFP
RPC39
= 39 kD 37.5 kD
marker
MCF7/GFP-PNRC MCF7/EGFP
1             2       3           4
B Blot: anti-GFP
56.7 kD
marker
IP          - RPC39
GFP-PNRC
= 60 kD
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Down regulation of RNA Pol III gene transcription by specific  depletion of endogenous PNRC using RNA interference Figure 4
Down regulation of RNA Pol III gene transcription by 
specific depletion of endogenous PNRC using RNA 
interference. A, Northern blot analysis of PNRC and 
GAPDH mRNAs. MCF7 cells were transiently transfected 
with Pol III reporter plasmid, pArg maxi, along with 20 nM of 
either siRNA specific for PNRC (PNRC/si) or nonspecific 
mismatch RNA (mm). Twenty-four hours after transfection, 
20 µg of total RNA, isolated from the transfected cells, was 
subjected to Northern analysis with PNRC and GAPDH 
cDNA probes, separately, as described in Methods section. 
B, Western blot of PNRC and actin protein. An aliquot of 
cell lysate equal to 100 µg of protein prepared from PNRC/
siRNA (20 nM) transfected (PNRC/si) or nonspecific mis-
match RNA (mm) transfected MCF7/EGFP-PNRC cells was 
separated on a 10% SDS-PAGE and subjected to Western 
analysis with 1:1000 diluted anti-GFP mouse monoclonal 
antibody (Cloetech) and anti-actin antibody (Santa Cruz Bio-
technology) separately. The protein bands with molecular 
weights corresponding to those of EGFP-PNRC fusion pro-
tein or actin were indicated by arrows. C, Down regulation 
of tRNAarg transcription by PNRC/siRNA. MCF-7 cells were 
transiently transfected with reporter plasmid, pArg maxi (10 
µg) along with 20 nM of either PNRC/siRNA (PNRC) or mis-
match control RNA (mm). Twenty-four hours after transfec-
tion, the levels of tRNA transcripts in the transfected cells 
were determined by RNase protection assay as described in 
figure 3.
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PNRC stimulates the transcription of tRNAarg gene by Pol III Figure 3
PNRC stimulates the transcription of tRNAarg gene 
by Pol III. MCF7 breast cancer cells (A) were transiently 
transfected with 10 µg of reporter plasmid pArg-maxi which 
contains a Drosophila tRNAarg gene and increasing amounts 
(0, 5, or 10 µg) of PNRC expression plasmid, pSG5-PNRC. 
Cells were cultured for 24 hours and the tRNAarg transcripts 
in 1 µg of total RNA isolated from the transfected cells was 
determined by RNase protection assay using a 32P-labeled 
antisense riboprobe. An example of an autoradiogram of 
tRNAarg transcript (indicated by an arrow) and quantification 
of the levels of tRNAarg mRNA from three independent 
experiments are shown. B, Western blot analysis of PNRC 
protein in MCF7/vector and MCF7/PNRC stably transfected 
cells. The procedures for transfection, G418 selection, and 
individual clone screening were described in Methods. An 
aliquot of cell lysate, from MCF7/vector or MCF7/PNRC 
cells, equal to 100 µg of protein was analysed by Western 
blot using PNRC antiserum (1:500 dilution) or anti-actin anti-
body (1:1000 dilution) as previously described [2]. The pro-
tein bands with molecular weights corresponding to those of 
PNRC or actin were indicated by arrows. C, MCF-7/vector 
or MCF7/PNRC stable expression cells were transiently 
transfected with 10 µg of reporter plasmid pArg-maxi. 
Twenty-four hours after transfection, the tRNAarg mRNA 
levels in the transfected cells were analysed by RNase pro-
tection assay as described for A. An example of an autoradio-
gram of tRNAarg transcript (indicated by an arrow) and 
quantification of the levels of tRNAarg mRNA from three 
independent experiments are shown.
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scribed by RNA pol III. These results suggest that PNRC
might be bound to these genes. To test this hypothesis, we
employed chromatin immunoprecipitation (ChIP) analy-
sis to examine the promoter occupancy of PNRC and
RPC39 on tRNAarg gene and U6 RNA gene promoters.
MCF-7/EGFP-PNRC cells were co-transfected with either
the tRNAarg gene or the U6 RNA gene, and the expression
plasmid for RPC39, pSG5-RPC39. MCF7/EGFP-PNRC
cells were chosen in this experiment because GFP anti-
body could be used to precipitate EGFP-PNRC bound pro-
moter regions of the RNA pol III transcribed genes. Results
in Fig. 5A showed that the tRNAarg gene was only ampli-
fied from the precipitates by anti-GFP (Fig. 5A, lane3) or
anti-RPC39 (Fig. 5A, lane 4) antibody. Only a very weak
band was amplified in the PCR reaction with the precipi-
tated DNA from the no antibody control reaction (Fig. 5A,
lane 2). To validate that the DNA fragment amplified was
the expected 220-bp region of the tRNAarg gene, this frag-
ment was subcloned into TA cloning vector and then
sequenced. Sequence data confirmed that the PCR prod-
uct has the sequence of tRNAarg gene (data not shown).
Similar results were obtained from the PCR analysis of
chromatin immunoprecipitates using the primer set for
the amplification of the U6 RNA gene (Fig. 5B). Together,
these results demonstrate recruitment of PNRC and
RPC39 to the genes transcribed by RNA pol III.
Discussion
In order to further characterize the role of PNRC in gene
activation, we sought to clone cellular proteins other than
the nuclear receptors that specially interact with the C-ter-
minus of PNRC harboring an SH3-binding motif. The
yeast two-hybrid interaction screen identified RPC39, an
RNA pol III-specific subunit, as one potential partner of
PNRC. Several independent methods confirmed the inter-
action and association of PNRC and RPC39 in vitro (Fig.
1) and in vivo (Fig. 2). Chromatin immunoprecipitation
assays revealed the presence of PNRC at tRNA and U6
RNA gene promoters in MCF-7 cells (Fig. 5). Accordingly,
tRNA gene transcription was induced when exogenous
PNRC was introduced into MCF-7 cells by either transient
transfection (Fig. 3A) or stable transfection (Fig. 3C). This
effect is not just a feature of PNRC overexpression. Specific
depletion from MCF-7 cells of endogenous PNRC using
RNA interference caused a five-fold decrease in tRNA gene
transcription (Fig. 4C). These results suggest that PNRC
can function as a modulator of RNA pol III transcription
by directly interacting with RPC39 subunit.
There are three RNA polymerases in eukaryotic cells, with
distinct functions. Each is responsible for synthesizing a
different set of products. RNA pol I synthesizes the large
rRNAs, RNA pol II synthesizes mRNAs and some untrans-
lated RNAs, whereas RNA pol III transcribes many
untranslated RNAs including tRNA, 5S rRNA, and U6
RNA. Human RNA pol III is the largest RNA polymerase
with the largest number of subunits [6]. It is composed of
at least 16 subunits and three of these, hRPC32, hRPC39,
and hRPC62, are specific for RNA pol III and play impor-
tant roles in accurate transcription initiation [5,7]. RNA
pol III plays a key role in cell growth control by catalyzing
the production of tRNA and 5S rRNA. Although this is
often regarded as a housekeeping function, it is in fact
highly regulated [8]. RNA pol III transcription increases
markedly when mammalian cell pass through the G1/S
transition [9,10]. Many types of transformed cell lines
have been shown to overexpress RNA pol III products.
Growth factors trigger a rapid increase in RNA pol III activ-
ity and this is essential for cell proliferation [11]. The
tumor suppressors, p53 and RB, have been demonstrated
to repress RNA pol III transcription through their interac-
tion with TFIIIB [8,12-15], while oncoproteins, including
Ras [16], c-Myc [17], E7 [18,19], and E1A [20,21],
strongly stimulate RNA pol III transcription by activating
TFIIIB directly or indirectly.
Co-recruitment of PNRC and RPC39 onto RNA polymerase  III-dependent genes Figure 5
Co-recruitment of PNRC and RPC39 onto RNA 
polymerase III-dependent genes. MCF-7/EGFP-PNRC 
cells were transfected either with pArg maxi reporter plas-
mid, which contains tRNAarg gene promoter and coding 
sequence, or with pTZU6 plasmid that carries the U6 RNA 
gene promoter. Twenty-four hours after transfection, cells 
were treated with formaldehyde to crosslink endogenous 
proteins and DNA. Samples of sonicated and purified chro-
matin were immunoprecipitated with no antibody (No ab), 
preimmuno IgG (IgG), GFP antibody (anti-GFP), or RPC39 
antibody (anti-RPC) as indicated. DNA isolated from immu-
noprecipitated material was amplified by PCR with primers 
to amplify a 220 bp fragment of the Drosophila tRNAarg gene 
(A) or a 160 bp fragment of the U6 RNA gene (B). The 
amplified PCR products were analyzed on 1.8% agarose gel. 
The PCR products from the reactions using input DNA, 
pArg or pTZU6 plasmids as template were included on the 
gels as positive and size controls.
MCF7/EGFP-PNRCcells transfected with pArg
100 bp     Input      No ab    anti-GFP  anti-RPC  pArg
200 bp
1            2              3            4              5
100 bp     Input        No ab      IgG anti-GFP  anti-RPC  pTZU6 
MCF7/EGFP-PNRC cells transfected with pTZU6
1              2      3             4           5       6     
200 bp
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After cloning of the first authentic steroid receptor coacti-
vator 1 (SRC-1) in 1995 [22], more than 50 nuclear recep-
tor cocativators have been cloned [23]. In general,
coactivator proteins do not bind to DNA, but interact
indirectly through association with other DNA-binding
proteins such as nuclear receptors. Hormone binding trig-
gers nuclear receptor translocation and the release of the
corepressor complex and subsequent recruitment of
nuclear receptor coactivator to the target gene promoters.
Once recruited to the promoter, coactivators enhance
RNA pol II transcription activity through a combination
of mechanisms, including efficient recruitment of basal
transcriptional factors. In addition, nuclear receptor coac-
tivators possess themselves, or recruit other nuclear pro-
teins that possess enzymatic activities crucial for efficient
gene expression including the acetyl-transferase (CBP/
p300 [24], pCAF [25], and p160s [26,27]), methyltrans-
ferases (CARM1 [28], PRMT-1 [29], and PRMT2 [30]) and
ubiquitin ligases (E6-AP [231 and Rsp5 [32]]). It has been
reported that p160 nuclear receptor coactivator such as
GRIP1 only selectively stimulates the transcription of RNA
pol II but not promoters transcribed by RNA pol III [33].
Previously, we demonstrated that PNRC interacts with
nuclear receptors and functions as a coactivator to
enhance transcription by RNA pol II, mediated by multi-
ple nuclear receptors [2]. Here, we demonstrate that
PNRC also stimulates transcription by RNA pol III
through its interaction with the RNA pol III-specific subu-
nit, RPC39. This finding makes PNRC a unique coactiva-
tor.
Materials and methods
Cell lines and reagents
MCF-7 cells, human breast adenocarcinoma cells, were
purchased from ATCC and were grown in Eargle's MEM
supplemented with 10% fetal bovine serum, 100 IU of
penicillin per ml, 100 µg of streptomycin per ml and non-
essential amino acid and sodium pyruvate. For the co-
immunoprecipitation experiment and down-regulation
of tRNAarg  transcription by PNRC/siRNA experiment,
MCF-7/EGFP-PNRC cells, which stably express the EGFP-
PNRC fusion protein, were used. The culture condition
was the same as that for MCF-7 cells except that 1 mg/ml
of G418 was included in the culture medium.
The MATCHMAKER Two-Hybrid System kit including a
human mammary gland MATCHMAKER cDNA library
was purchased from Clontech (Palo Alto, CA). Yeast trans-
formation kit was purchased from Bio 101 (La Jolla, CA),
and the yeast culture media were purchased from Clon-
tech. Various restriction endonuclease were purchased
from New England Biolabs (Beverly, MA). Hot start Taq
polymerase was purchased from Qiagen (Valencia, CA).
siRNA for PNRC was purchased from Ambion (Austin,
Texas). Anti-RPC39 mouse monoclonal antibody and
anti-actin were obtained from Santa Cruz Biotechnology,
Inc. (Santa Cruz, CA). Anti-GFP antibody was purchased
from Clontech. Anti-PNRC antiserum was generated as
previously described [4]. Lipofectamine 2000 was pur-
chased from Invitrogen Corporation (Carlsbad, CA).
ExpressHyb solution was purchased from Clontech. [α-
32P dCTP] was purchased from ICN Biomedicals, Inc.
(Irvine, CA) and the Megaprime DNA labeling kit was
obtained from Amersham Biosciences (Piscataway, NJ).
Oligonucleotide primers were synthesized in the DNA/
RNA chemistry laboratory at the City of Hope. DNA
sequencing was done in City of Hope Sequencing Core
facility.
Construction of plasmids
All recombinant DNA and plasmid constructions were
prepared according to standard procedures, and the
sequences and orientations of inserted DNA fragments in
plasmid constructs were verified by standard DNA
sequencing. Yeast expression plasmids for DBDGal4-
PNRC270–327 or DBDGal4-PNRC fusion proteins, named
pGBKT7-PNRC270–327 or pGBKT7-PNRC, were prepared
by inserting PCR-amplified coding regions for PNRC270–
327  or for the full length PNRC into pGBKT7 vector
through Nde1 and Sal1 sites, respectively. The plasmid for
the expression of DBDGal4-PNRC2 was prepared by insert-
ing the PCR-amplified PNRC2-coding region into
pGBKT7 vector through the Nde1 and Sal1 sites. The con-
struction of the plasmids for the expression of DBDGal4-
SF1, DBDGal4-hER/HBD, and DBDGal4-mERR3/HBD
were previously described [2,3].
The expression plasmids for the expression of ADGal4-
RPC39 and ADGal4-RPC391–211 were generated as fol-
lows. The coding regions of RPC39 and RPC391–211 were
amplified by PCR using pOTB7/RPC39 plasmid (Invitro-
gen) as template. The primers for PCR amplification of
RPC39 coding sequence are 5'GCCGAATTCCCATGGCG-
GAGGTGAAGGTG-3' and 5'-CGGCTCGAGCTAAAATTC-
GAGCCACTCTGTCAT-3' and the primers for PCR
amplification of RPC391-211 coding region are 5'-
GCCGAATTCCCATGGCGGAGGTGAAGGTG-3' and
5'CGGCTCGAGCTAGGCA-AATGAACTATTTCT-3'. The
EcoR1 and Xho1 digested PCR products were then inserted
into pACT2 vector at EcoR1 and Xho1 sites.
The GFP-PNRC expression plasmid (i.e. pEGFP-PNRC)
was constructed by inserting the human PNRC coding
region into the Bgl II/Sal I sites at the 3' end of the coding
region of the GFPmut1 variant in the pEGFP-C1 vector
(Clontech Laboratories, Inc.). The expression plasmid for
PNRC-V56His was generated using Echo Cloning System
(Invitrogen) that quickly and easily recombines a gene of
interest into a series of recipient (acceptor) vector. Briefly,
the coding region for wild type PNRC was amplified byJournal of Molecular Signaling 2007, 2:5 http://www.jmolecularsignaling.com/content/2/1/5
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PCR using pUC13-B4-2 [34] as template and forward
primer, 5'-GCCCTCGAGATGACTGTCGTCTCCGTCCCG-
3', and reverse primer, 5'-AATGAGCTCAGTTTGAACTTT-
GAGGAGGGT-3'. The PCR product was purified by agar-
ose gel electorphoresis, digested with Xho1 and Sac1, and
subcloned into a donor vector, pUni/V5-HisA (Invitro-
gen) through Xho1/Sac1 sites so that V5-6His is placed at
the C-terminus of PNRC. The recombinant donor plas-
mid, pUni-PNRC-V56His, was then mixed with the adap-
tor vector, pcDNA3.1E (Invitrogen), in the presence of Cre
recombinase. The recombination reaction mixture was
then transformed into TOP10 E. coli and the recom-
binants were selected by plating the transformation reac-
tion onto plates containing kanamycin. The
transformants were analyzed for recombinant plasmid,
pcDNA3.1E/pUni-PNRC-V56His, by restriction digestion
and sequencing. The RPC39 expression plasmid in mam-
malian cells, pSG5-RPC39, was generated by inserting the
PCR-amplified RPC39 coding region into pSG5 vector at
EcoR1/Bgl II sites.
Yeast two-hybrid screening
The yeast MATCHMAKER two-hybrid system (Clontech)
was used to screen a MATCHMAKER mammary gland
cDNA expression library according to the supplier's proto-
col (Clontech protocol PT1030-1) using pGBKT7-
PNRC270–327  as the bait. Briefly, the bait plasmid,
pGBKT7-PNRC270–327, was transformed into yeast
reporter stain CG1945 along with a human mammary
gland MATCHMAKER cDNA expression library (Clon-
tech) in the Gal4 activation domain vector (pACT2, Clon-
tech). Transformants (3.42 × 106) were screened first for
HIS3 reporter gene expression by plating them onto plates
lacking histidine, leucine, and tryptophan, and His+/Leu+/
Trp+ transformants were recovered and further screened
for β-galactosidase activity using the colony-lift filter assay
according to the supplier's protocol. Plasmids of both
His+ and β-galactosidase positive transformants were iso-
lated from yeast. The nucleotide sequences of inserts in
true positive hybrid plasmids were generated, and the
identity of the cDNAs was determined through a homol-
ogy search against known sequences in GenBank.
Yeast two-hybrid assay to detect the interaction between 
two known proteins
Yeast two-hybrid assay was used to examine protein-pro-
tein interaction in vivo. Briefly, the yeast strain Y187 was
co-transformed with the AD vector alone or AD-RPC39
wild type or its fragments along with pGBT9 (DBDGal4 vec-
tor only), pGBT9-/target plasmids (for PNRC 270–327,
SF1, ER/HBD, and mERR3/HBD) or DBD-hLC negative
control plasmid. The transformants that carry both plas-
mids were selected by plating them onto SD/-Leu/-Trp
plates and were further analyzed for β-galactosidase activ-
ity by liquid β-galactosidase activity measurement as
essentially described in the protocol. Briefly, the trans-
formants that grew on SD/-Leu/-Trp agar plates were cul-
tured overnight in liquid SD/-Leu/-Trp medium at 30°C.
This overnight culture was diluted in liquid YPD and then
continued to incubate for four to six hours. At the end of
this incubation, a liquid β-Galactosidase activity assay,
using ONPG as a substrate, was performed according to
the manufacturer's protocol (Clontech).
Western blot and coimmunoprecipitation
Western analyses were done as previously described [2].
The immunoprecipitation experiments with antibodies
against GFP (for the detection of EGFP-PNRC fusion pro-
tein) or RPC39 antibody were performed using an immu-
noprecipitation kit (protein A) (Roche Molecular
Biochemicals, Mannheim, Germany) according to the
manufacturer's instructions. Briefly, the lysis buffer (ice
cold, 50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1% Noni-
det P40, 0.5% sodium deoxycholate, and the complete set
of protease inhibitor cocktail) was added to the PBS-
washed cells. After 20 minutes of incubation on ice, the
cells were then scraped and transferred into Eppendorf
tubes, sonicated, and centrifuged at 12,000 × g at 4°C for
10 minutes. The amount of cell lysate used for immuno-
precipitation was 15 mg. To reduce background, aliquots
of cell lysats were mixed with 50 µl of the homogeneous
protein A agarose suspension and incubated at 2~8°C
overnight on a rocking platform. The agarose beads were
removed by centrifugation at 12,000 × g at 4°C for 20 sec-
onds. The supernatant was then incubated with the spe-
cific antibodies against GFP (1:1000) or RPC39 (1: 500
dilution) and gently rocked for 1 hour at 4°C. A 50 µl of
the homogeneous protein A agarose suspension was
added and incubated further at 2~8°C overnight on a
rocking platform. The complexes were collected by cen-
trifugation at 12,000 × g at 4°C for 20 seconds. The pre-
cipitates bound beads were washed each time using
washing buffer 1 (same as lysis buffer), washing buffer 2
(ice cold, 50 mM Tris-HCl, pH 7.5, 500 mM NaCl, 0.1%
Nonidet P40, 0.05% sodium deoxycholate) and washing
buffer 3 (ice cold, 10 mM Tris-HCl, pH 7.5, 0.1% Nonidet
P40, 0.05% sodium deoxycholate). The bead bound pre-
cipitates were eluted with gel loading buffer, separated on
a 12% SDS-PAGE, and detected by Western blotting, using
either the GFP antibody or RPC39 antibody. To check
whether EGFP-PNRC and RPC39 expressed in the cells,
100 µg of lysate was also included in each corresponding
gel for Western analysis. The immuno-protein complex
was detected by a 1:1000 diluted goat anti-rabbit horse-
radish peroxidase conjugate (Pierce Chemical Co.) fol-
lowed by the DAB (diaminobenzidine
tetrahydrochloride, Sigma) substrate visualization.Journal of Molecular Signaling 2007, 2:5 http://www.jmolecularsignaling.com/content/2/1/5
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Establishment of PNRC stable expression MCF-7 cell lines
MCF-7 cells in 6-well plate were transfected with 5 µg of
either expression vector pEGFP-C1 (Clontech) or
pcDNA3.1E (Invitrogen) or expression plasmids for either
EGFP-PNRC fusion protein (pEGFP-PNRC) or PNRC-
VA6His (pcDNA3.1E-PNRCVA6His) using Lipofectamine
2000. At 48 h after transfection, the transfected cells were
split in fresh medium containing G418 (1 mg/ml) at 25%
confluent and were cultured in this selection medium
continuously until G418-resistant foci can be identified
(for about three weeks). The G418 resistant, pEGFP or
pEGFP-PNRC transfected MCF-7 cells were pooled and
further selected by flow cytometry cell sorting on the base
of their GFP fluorescence. For pcDNA3.1E or pcDNA3.1-
PNRC-V56His transfected MCF-7 cells, the individual
G418-resistant foci was picked and expanded in 24-well
plates. Individual G418 resistant clones were screened for
the highest level of PNRC expression by Northern blot,
Western blot, and PNRC coactivation function analysis.
RNase protection assay
RNase protection assays were carried out basically as pre-
viously described [35]. Briefly, MCF-7 cells were cotrans-
fected with the expression plasmid for PNRC, pSG5-
PNRC, and pArg-maxi gene for 24 h using Lipofectamine
2000. In some cases, the MCF7/PNRC cells that stably
express PNRC were transfected with only the pArg-maxi
gene for 24 h. For examining the effect of PNRC siRNA on
Pol III transcription, MCF-7 cells were co-transfected with
pArg-maxi gene along with either mismatch RNA or
siRNA specific for human PNRC gene. Total RNA was iso-
lated from the transfected cells by Trizol reagent (Invitro-
gen). RNase protection assays were carried out as
described in the protocol of Ambion, Inc. The 32P-labeled
riboprobe for tRNAarg gene was prepared as follows. The
pArg-maxi gene plasmid was digested with Xba1, and
labeled RNA probe was synthesized using the MAXIscript
T7 kit (Ambion) with [32P]CTP. Total RNA (1 µg) isolated
from the transfected cells was hybridized with the labeled
tRNAarg RNA probe and incubated at 40°C overnight. The
samples were digested with RNase A/T1 at 37°C for 30
min and precipitated. The samples were incubated on dry
ice for 15 min and centrifugated at 14, 000 rpm for
another 15 min. The pellets were resuspended in gel load-
ing buffer (Ambion) and separated on 8% acrylaminde-8
M urea denaturing gels. The bands were visualized by
autoradiography, and the RNA products were quantified
by Phosphorimager.
PNRC/siRNA transfection and cell proliferation analysis 
using RT-CES
The purified and annealed PNRC siRNA with the target
sequences of 5'-GGAAAGAGUUUUAAAAUCtt (sense)
and 5'-GAUUUUAAAACCUCUUUCCtg (antisense) was
purchased from Ambion. MCF-7 or MCF-7/EGFP-PNRC
cells in 6 well plates were transfected with 2 µl of siPORT
Lipid (Ambion) alone (mock transfection) or together
with 20 nM of PNRC siRNA or control siRNA, GAPDH
negative control siRNA, according to the manufacturer's
instruction. At 8 h, 24 h or 48 h after transfection, cell
lysate (100 µg) or total RNA (20 µg), prepared from the
transfection cells, was subjected to Western blot as previ-
ously described [2] or Northern analysis as described
below.
Northern hybridization
Total RNA was isolated from MCF7 cells using TRIzol rea-
gent (Invitrogen). Twenty µg total RNA was analyzed by
Northern hybridization. After being fractionated on a
1.0% agarose/formaldehyde gel by electrophoresis, RNA
was transferred overnight in 10× SSC onto a Zeta Probe
GT membrane (Bio-Rad) and the membrane was baked at
80°C for 1 hour. A 740-bp human PNRC cDNA was gen-
erated by EcoR1 restriction digestion of pSG5-PNRC plas-
mid and gel purification. 100 ng of this DNA fragment
was radioactively labeled with [α-32P] dCTP (ICN) using
the Megaprime DNA labeling kit (Amersham Biosciences)
and used as probe in hybridization at the concentration of
2 × 106 cpm/ml. The membrane was wet in 5 × SSC before
prehybridized in ExpressHyb solution (Clontech) at 68°C
for 30 min and hybridized at 68°C for 1 hour. The mem-
brane was then rinsed twice with 2× SSC/0.05% SDS and
washed twice, each 15 min, with same buffer at room tem-
perature. If necessary, the membrane was further washed
with 0.1 × SSC/0.1% SDS at 50°C for 5–15 min and
exposed to X-ray film (Kodak) overnight at -70°C. After
stripping off the PNRC2 probe, by washing in the boiling
0.5% SDS for 10 min at room temperature, the membrane
was hybridized with a 32P-labeled 840-bp human GAPDH
cDNA probe, generated by RT-PCR, using the following
forward and reverse primers: 5'-ACA GCC GCA TCT TCT
TGT GCA GTG-3' and 5'-TCA GAT GCC TGC TTC ACC
ACC TTC-3'.
Chromatin immunoprecipitation assay (ChIP)
ChIP assay was performed using ChIP Assay kit (Upstate)
according to the manufacturer's instructions. Briefly,
approximately 106 of MCF-7/RGFP-PNRC cells cultured
in 10 cm dish were transiently transfected with pArg maxi
(contains tRNAarg gene) or pTZU6 (contains U6 RNA
gene). Twenty-four hours after transfected, cells were
treated with 1% formaldehyde (final concentration, v/v)
in cell culture medium for 10 min at 37°C to cross-link
proteins to DNA. The cells were washed twice with phos-
phate-buffered saline, pH 7.4 containing protease inhibi-
tor cocktail (Roche Molecular Biochemicals), harvested by
centrifugation and resuspended in 200 µl SDS lysis buffer
(1% SDS, 10 mM EDTA, 50 mM Tris-HCl (pH 8.1), and
protease inhibitor cocktail) and incubated on ice for 10
min. Samples were sonicated on ice with a Digital SonifierJournal of Molecular Signaling 2007, 2:5 http://www.jmolecularsignaling.com/content/2/1/5
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(Dranson Ultrasonics Corporation, CT) at 30% of maxi-
mum power 10 times for 15 s each, with 2 min of cooling
on ice in between sonications.
The sonicated DNA was diluted 10-fold in ChIP dilution
buffer (0.01% SDS, 1.1% Triton X-100, 1.2 mM EDTA,
16.7 mM Tris-HCl (pH8.1), 167 mM NaCl, and protease
inhibitor cocktail). A fraction of the diluted supernatant,
1%, or ~20 µl, was transferred to a new tube and kept as
input for PCR. The rest of the supernatant was pre-cleared
by incubation with protein A Sepharose beads for 2 hours
at 4°C. The antibodies against GFP (for EGFP-PNRC
fusion protein) or RPC39 (2 µg each) were then added
and the samples were incubated overnight at 4°C. For a
negative control, a no antibody immunoprecipitation or
normal rabbit IgG immunoprecipitation was also per-
formed. Immunocomplexes were precipitated for 2 hours
with protein A Sepharose beads and the precipitates were
washed once with 1 ml of low salt wash buffer (0.1% SDS,
1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl (pH 8.1),
and 150 mM NaCl), once with 1 ml of high salt wash
buffer (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM
Tris-HCl (pH 8.1), and 500 mM NaCl), once with LiCl
wash buffer (0.25 M LiCl, 1% IGEPAL-CA630, 1% deoxy-
cholic acid (sodium salt), 1 mM EDTA, 10 mM Tris, pH
8.1), and twice with TE buffer. All washes were for 5 min,
rotating at 4°C. The protein/DNA complexes were eluted
from beads with 250 µl of elution buffer (1% SDS, 0.1 M
NaHCO3). Formaldehyde cross-links were reversed by
overnight incubation at 65°C and the proteins subse-
quently degraded by proteinase K. DNA was recovered by
phenol-chloroform extraction and ethanol precipitation
in the presence of 0.3 M sodium acetate and 20 µg glyco-
gen. PCR amplification of a 220 bp of the Drosophila
tRNAarg gene was performed using a sense primer 5'-ATG
TAC ACT AGA GTA GTA TCC ACA TAT-3' and an anti-
sense primer 5'-CTA GCT AGT TGA TGC ACT GCT TGG
AGG-3' [36]. PCR amplification for a 160 bp fragment of
U6 RNA gene was also performed using a forward primer
5'-GTACAAAATACGTGACGTAGAAAG-3' and a reverse
primer 5'-GGTGTTTCGTCCTTTCCAC-3' [37]. HotStarTaq
DNA polymerase (Qiagen) was used to perform PCR uti-
lizing the following conditions: Initial denaturation for
15 min at 95°C followed by 40 cycles of denaturation at
95°C for 1 min, annealing at 55°C for 1 min, extension at
72°C for 1 min ending with a final 7 min extension at
72°C. The PCR products were resolved electrophoretically
on a 1.6% agarose gel and visualized with EtBr staining.
The PCR products were further subcloned into TA cloning
vector (Invitrogen) and sequenced.
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